IgA-nefropátia: vizsgálatok itt: Izrael

4 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

• 3. fázisTaking people
  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  Where

  Ashkelon, Jerusalem, Petah Tikva

  Életkor

  18 év to 100 év

  People

  540 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT04557462 · EU 2023-508690-92-00
• 3. fázisTaking people
  Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

  Where

  Beersheba, Haifa, Jerusalem, Petah Tikva

  Életkor

  2 év to 18 év

  People

  31 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT06994845
• 2. fázisTaking people
  Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

  Where

  Ashdod, Hadera, Haifa, Nahariya

  Életkor

  18 év to 99 év

  People

  20 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT06797518
• 2/3. fázisCsak meghívásos
  Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

  Where

  Ashkelon, Kfar Saba, Nahariya, Petach Tiqwa

  Életkor

  18 év and over

  People

  600 worldwide

  Run by

  Otsuka Pharmaceutical Development & Commercialization, Inc.

  See details and how to joinNCT05248659